Effective PAD (bortezomib, doxorubicine, dexamethasone) treatment of a patient with plasma cell leukaemia developed after autologous stem cell transplantation;Autológ ossejt-transzplantációt követoen kialakult plazmasejtes leukémia hatékony kezelése PAD - (bortezomib, doxorubicin, dexamethason) protokoll alkalmazásásval

Orvosi Hetilap

Volumn 149, Issue 41, 2008, Pages 1957-1959

  Telek, Béla ^a,b   Méhes, Leonóra ^a   Batár, Péter ^a   Kiss, Attila ^a   Udvardy, Miklós ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b NONE   (Hungary)

Author keywords

Autologous transplantation; Bortezomib; Multiple myeloma; Plasma cell leukaemia

Indexed keywords

BORTEZOMIB; CISPLATIN; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; METHOTREXATE; VINCRISTINE;

ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; HUMAN; LEUKEMIA REMISSION; MALIGNANT TRANSFORMATION; MULTIPLE MYELOMA; PLASMA CELL LEUKEMIA; SURVIVAL TIME;

EID: 55749106017     PISSN: 00306002     EISSN: 17886120     Source Type: Journal    
DOI: 10.1556/OH.2008.28432     Document Type: Article

References (13)

1. Musto, P., Rossini, F., Gay, F. és mtsai: Efficacy and safety of bortezomib in patients with plasma cell leukaemia. Cancer, 2007, 109, 2285-2290.
2. Gertz, M. A.: Managing plasma cell leukemia. Leuk. Lymph., 2007, 48, 5-6.
3. Petrucci, M. T., Martini, V., Levi, A. és mtsai: Thalidomide does not modify the prognosis of plasma cell leukemia patients: Experience of a single center. Leuk. Lymph., 2007, 48, 180-182.
4. Anargyrou, K., Dimopoulos, M-A., Sezer, O. és mtsa: Novel antimyeloma agents and angiogenesis. Leuk. Lymph., 2008, 49, 677-689.
5. Hideshima, T., Bergsagel, P. L., Kuehl, W. M. és mtsa: Advances in biology of multiple myeloma: clinical applications. Blood, 2004, 104, 607-618.
6. Richardson, P. G., Barlogie, B., Berenson, J. és mtsai: A Phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med., 2003, 348, 2609-2617.
7. Oakervee, H., Popat, R., Cavenagh, J. D.: Use of bortezomib as induction therapy prior to stem cell transplantation in frontline treatment of multiple myeloma: Impact on stem cell harvesting and engraftment. Leuk. Lymph., 2007, 48, 1910-1921.
8. Ataergin, S., Arpaci, F., Kaya, A. és mtsai: VAD combination chemotherapy followed by bortezomib may be effective treatment in secondary plasma cell leukemia. Am. J. Hematol., 2006, 81, 987-988.
9. Capalbo, S., Chiefa, A., Delia, M. és mtsai: Effective combination therapy of bortezomib and dexamethasone for a plasma cell leukemia with multiple osteolytic lesions and extramedullary involvement. Acta Oncol., 2007, 46, 262-264.
10. Esparis-Ogando, A., Alegre, A., Aguado, B. és mtsai: Bortezomib is an efficient agent in plasma cell leukemias. Int. J. Cancer, 2005, 114, 665-667.
11. Finnegan, D. P. J., Kettle, P., Drake, M. és mtsai: Bortezomib is effective in primary plasma cell leukemia. Leuk. Lymph., 2006, 47, 1670-1673.
12. Badros, A., Goloubeva, O., Datal, J. S. és mtsai: Neurotoxicity of bortezomib therapy in multiple myeloma: A single-center experience and review of the literature. Cancer, 2007, 110, 1042-1049.
13. Saccaro, S., Fonseca, R., Veillon, D. M. és mtsai: Primary plasma cell leukemia: Report of 17 new cases treated with autologous or allogeneic: stem-cell transplantation and review of the literature. Am. J. Hematol., 2005, 78, 288-294.